Circulating APP, NCAM and Aβ serve as biomarkers for Alzheimer's disease
Copyright © 2018 Elsevier B.V. All rights reserved..
Alzheimer's disease (AD) is the most common neurodegenerative disease and the early diagnosis and intervention are important for valid treatment of AD. However, there are few biomarkers for the diagnosis and monitoring of AD. In the present study, circulating APP, NCAM, Aβ40, and Aβ42 were measured in order to identify which marker or combination of markers could be useful, cost-effective and noninvasive biomarkers for diagnosing and continuously monitoring AD. The results showed that circulating APP, NCAM, Aβ40, and Aβ42 were different between the AD group and the control group. Importantly, the combination of the four biomarkers had the highest AUC (0.997) with the highest sensitivity (98.5). Therefore, circulating APP, NCAM, Aβ40, and Aβ42 can be used as desirable biomarkers for AD diagnosis and monitoring.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1699 |
|---|---|
| Enthalten in: |
Brain research - 1699(2018) vom: 15. Nov., Seite 117-120 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Keping [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.09.2019 Date Revised 30.09.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.brainres.2018.08.015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM287574423 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM287574423 | ||
| 003 | DE-627 | ||
| 005 | 20231225054322.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.brainres.2018.08.015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0958.xml |
| 035 | |a (DE-627)NLM287574423 | ||
| 035 | |a (NLM)30118716 | ||
| 035 | |a (PII)S0006-8993(18)30435-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Keping |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Circulating APP, NCAM and Aβ serve as biomarkers for Alzheimer's disease |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.09.2019 | ||
| 500 | |a Date Revised 30.09.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 Elsevier B.V. All rights reserved. | ||
| 520 | |a Alzheimer's disease (AD) is the most common neurodegenerative disease and the early diagnosis and intervention are important for valid treatment of AD. However, there are few biomarkers for the diagnosis and monitoring of AD. In the present study, circulating APP, NCAM, Aβ40, and Aβ42 were measured in order to identify which marker or combination of markers could be useful, cost-effective and noninvasive biomarkers for diagnosing and continuously monitoring AD. The results showed that circulating APP, NCAM, Aβ40, and Aβ42 were different between the AD group and the control group. Importantly, the combination of the four biomarkers had the highest AUC (0.997) with the highest sensitivity (98.5). Therefore, circulating APP, NCAM, Aβ40, and Aβ42 can be used as desirable biomarkers for AD diagnosis and monitoring | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a Amyloid-precursor protein | |
| 650 | 4 | |a Circulating biomarker | |
| 650 | 4 | |a Neural cell adhesion molecule | |
| 650 | 4 | |a β-Amyloid | |
| 650 | 7 | |a APP protein, human |2 NLM | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 650 | 7 | |a Amyloid beta-Protein Precursor |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Neural Cell Adhesion Molecules |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a amyloid beta-protein (1-40) |2 NLM | |
| 650 | 7 | |a amyloid beta-protein (1-42) |2 NLM | |
| 700 | 1 | |a Gao, Tianli |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Zhimao |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Zuanning |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain research |d 1966 |g 1699(2018) vom: 15. Nov., Seite 117-120 |w (DE-627)NLM000001538 |x 1872-6240 |7 nnns |
| 773 | 1 | 8 | |g volume:1699 |g year:2018 |g day:15 |g month:11 |g pages:117-120 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.brainres.2018.08.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1699 |j 2018 |b 15 |c 11 |h 117-120 | ||